| Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients EQ Wu, S Johnson, N Beaulieu, M Arana, V Bollu, A Guo, J Coombs, ... Current medical research and opinion 26 (1), 61-69, 2010 | 168 | 2010 |
| Estimating Alzheimer's disease progression rates from normal cognition through mild cognitive impairment and stages of dementia M Davis, T O'Connell, S Johnson, S Cline, E Merikle, F Martenyi, ... Current Alzheimer Research 15 (8), 777-788, 2018 | 156 | 2018 |
| Integrated telehealth and care management program for Medicare beneficiaries with chronic disease linked to savings LC Baker, SJ Johnson, D Macaulay, H Birnbaum Health Affairs 30 (9), 1689-1697, 2011 | 147 | 2011 |
| Risk of developing comorbidities among women with endometriosis: a retrospective matched cohort study ES Surrey, AM Soliman, SJ Johnson, M Davis, J Castelli-Haley, ... Journal of women's health 27 (9), 1114-1123, 2018 | 88 | 2018 |
| Impact of a patient support program on patient adherence to adalimumab and direct medical costs in Crohn’s disease, ulcerative colitis, rheumatoid arthritis, psoriasis … DT Rubin, M Mittal, M Davis, S Johnson, J Chao, M Skup Journal of managed care & specialty pharmacy 23 (8), 859-867, 2017 | 82 | 2017 |
| An economic model of P arkinson's disease: Implications for slowing progression in the United States SJ Johnson, MD Diener, A Kaltenboeck, HG Birnbaum, AD Siderowf Movement Disorders 28 (3), 319-326, 2013 | 75 | 2013 |
| Direct costs and survival of medicare beneficiaries with early and advanced Parkinson’s disease A Kaltenboeck, SJ Johnson, MR Davis, HG Birnbaum, CA Carroll, ... Parkinsonism & related disorders 18 (4), 321-326, 2012 | 72 | 2012 |
| The" crisis" in medical malpractice insurance PM Danzon, AJ Epstein, SJ Johnson Brookings-Wharton papers on financial services 2004 (1), 55-96, 2004 | 67 | 2004 |
| Cost-effectiveness of voretigene neparvovec-rzyl vs standard care for RPE65-mediated inherited retinal disease S Johnson, M Buessing, T O’Connell, S Pitluck, TA Ciulla JAMA ophthalmology 137 (10), 1115-1123, 2019 | 62 | 2019 |
| Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn’s disease AP Yu, S Johnson, ST Wang, P Atanasov, J Tang, E Wu, J Chao, ... Pharmacoeconomics 27, 609-621, 2009 | 51 | 2009 |
| Effects of care management and telehealth: a longitudinal analysis using medicare data LC Baker, DS Macaulay, RA Sorg, MD Diener, SJ Johnson, HG Birnbaum Journal of the American Geriatrics Society 61 (9), 1560-1567, 2013 | 49 | 2013 |
| Costs of Parkinson’s disease in a privately insured population SJ Johnson, A Kaltenboeck, M Diener, HG Birnbaum, EB Grubb, ... Pharmacoeconomics 31, 799-806, 2013 | 46 | 2013 |
| Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy A Lloyd, N Piglowska, T Ciulla, S Pitluck, S Johnson, M Buessing, ... British Journal of Ophthalmology 103 (11), 1610-1614, 2019 | 45 | 2019 |
| Cost-effectiveness of adalimumab for the maintenance of remission in patients with Crohn's disease EV Loftus Jr, SJ Johnson, PY Andrew, EQ Wu, J Chao, PM Mulani European journal of gastroenterology & hepatology 21 (11), 1302-1309, 2009 | 41 | 2009 |
| Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA DS Chu, SJ Johnson, UG Mallya, MR Davis, RA Sorg, MS Duh Journal of Ophthalmic Inflammation and Infection 3, 1-10, 2013 | 38 | 2013 |
| An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes SD Ramsey, LD Clarke, CS Roberts, SD Sullivan, SJ Johnson, LZ Liu Pharmacoeconomics 26, 329-339, 2008 | 37 | 2008 |
| Economic and developmental considerations for pharmacogenomic technology JA Vernon, SJ Johnson, WK Hughen, A Trujillo Pharmacoeconomics 24, 335-343, 2006 | 36 | 2006 |
| Early retirement and income loss in patients with early and advanced Parkinson’s disease S Johnson, M Davis, A Kaltenboeck, H Birnbaum, EB Grubb, M Tarrants, ... Applied Health Economics and Health Policy 9, 367-376, 2011 | 34 | 2011 |
| Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial R Panaccione, JF Colombel, SPL Travis, P Bossuyt, F Baert, T Vaňásek, ... Gut 69 (4), 658-664, 2020 | 32 | 2020 |
| Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis JI Silverberg, HC Hong, JP Thyssen, BM Calimlim, A Joshi, HD Teixeira, ... Dermatology and therapy 12 (5), 1181-1196, 2022 | 31 | 2022 |
Andrew J EpsteinMedicus EconomicsVerified email at medicuseconomics.com
